Biomolecular Characterization Device
RedShift BioAnalytics Inc.Request Info
BURLINGTON, Mass., May 17, 2022 —
The Apollo biomolecular characterization device from RedShift BioAnalytics Inc. uses microfluidic modulation spectroscopy (MMS) technology to provide sensitive, precise measurements of biomolecule structures.
Users are able to compare higher-order structure and similarity profiles for confidence in structural similarity and activity to inform discovery, screening, formulation, and quality control in biopharmaceutical drug development. The device provides accurate and reproducible measurements with a broad concentration range from 0.1 mg/ml to >200 mg/ml, allowing measurement in native conditions.
https://www.redshiftbio.com
https://www.photonics.com/Buyers_Guide/RedShift_BioAnalytics_Inc/c12636
Photonics.com
May 2022